Composition comprising lactobacillus gasseri for preventing and treating sarcopenia

Abstract

The present invention relates to a composition comprising Lactobacillus gasseri for preventing and treating sarcopenia and, in particular, to: a composition comprising Lactobacillus gasseri BNR17 for preventing and treating sarcopenia, the composition is used for preventing, treating or relieving sarcopenia, muscle quality and muscle function decline and muscle strength and muscle endurance decline which are induced by stress, obesity, aging, drugs, tumors and the like.

Description

Technical Field

[0001] The present invention relates to a composition comprising Lactobacillus gasseri for preventing or treating sarcopenia, and more particularly, to a composition comprising Lactobacillus gasseri BNR17 for preventing, treating or alleviating sarcopenia, decreased muscle mass and muscle function, and decreased muscle strength and muscle endurance caused by factors such as stress, obesity, aging, drugs, tumors, etc. Background Art

[0002] Lactobacillus is a gram-positive bacterium that mainly produces lactic acid due to fermentation and is also called lactic acid bacteria. It includes bacteria belonging to the family Lactobacilales and is distributed in fermented foods such as yogurt, cinchi, etc., intestinal tract, and milk.

[0003] It is known that lactic acid bacteria are beneficial to human health, such as preventing the proliferation of harmful bacteria in the intestine and regulating immunity to a normal range. Conventional technologies using lactic acid bacteria include Korean Patent Application Publication No. 10-2013-0002545 (novel lactic acid bacteria and compositions including the same for preventing and treating diabetes), Korean Patent Application Publication No. 10-2018-0087662 (a pharmaceutical composition including a cysteine ​​protease inhibitor and a protein derived from lactic acid bacteria for treating colorectal cancer), etc.

[0004] Lactobacillus gasseri is a lactic acid bacteria species in the genus Lactobacillus. Lactobacillus gasseri is known to have effects on rheumatoid arthritis (Korean Patent Application Publication No. 10-2021-0043797), antifungal activity (Korean Patent No. 10-2063554), etc., but its more diverse physiological effects need to be studied.

[0005] Lactobacillus gasseri BNR17 is a strain belonging to the species Lactobacillus gasseri isolated from Korean breast milk.

[0006] Meanwhile, sarcopenia is a disease in which muscle mass, muscle strength and muscle function are reduced due to various factors. The factors that lead to sarcopenia vary from person to person, but common factors include: insufficient protein intake including essential amino acids, lack of exercise, aging, hormonal changes, side effects of drugs, etc. In addition to diseases occurring in the muscles themselves, sarcopenia is also secondary to cancer, diabetes, chronic diseases of the heart, lungs and kidneys, hormonal diseases, degenerative diseases (such as spinal stenosis, etc.) and acute diseases (such as infection, etc.).

[0007] Symptoms of sarcopenia include muscle weakness, frailty and fatigue. Muscle mass and strength naturally decrease with age, but even after accounting for age and gender, sarcopenia leads to decreased physical function due to excessive loss of muscle mass and strength, which increases health risks and mortality. Patients with sarcopenia have reduced muscle strength and endurance, are susceptible to osteoporosis, falls and fractures, and have an increased risk of diabetes and cardiovascular disease due to a reduced basal metabolic rate.

[0008] Sarcopenia is diagnosed by measuring muscle mass, muscle strength, and muscle function. Muscle mass in the human body is measured using methods such as dual-energy X-ray absorptiometry, bioimpedance analysis, CT, MRI, etc. Muscle strength is measured by leg strength or grip strength, and muscle function is measured by walking speed test, 400-meter walk test, 6-minute walk test, etc.

[0009] There is currently no treatment for sarcopenia, and the only way to delay the onset of sarcopenia is to consume protein containing essential amino acids, muscle strength training and aerobic exercise.

[0010] Therefore, there is a growing need to improve health and quality of life by developing safe and effective methods to inhibit sarcopenia in humans, as well as to prevent, alleviate or treat sarcopenia caused by various factors.

[0011] Against this technical background, the inventors of the present application have determined that Lactobacillus gasseri BNR17 is effective in preventing or treating sarcopenia, thereby contributing to the present invention. Summary of the invention

[0012] The present invention aims to provide a composition for preventing or treating sarcopenia, the composition comprising Lactobacillus gasseri. The present invention aims to provide a method for preventing or treating sarcopenia, the method comprising administering Lactobacillus gasseri. The present invention aims to provide the use of a composition comprising Lactobacillus gasseri for preventing or treating sarcopenia.

[0013] Another object of the present invention is to provide a composition for alleviating the decline in muscle mass and muscle function, the composition comprising Lactobacillus gasseri. The present invention aims to provide a method for alleviating the decline in muscle mass and muscle function, the method comprising administering Lactobacillus gasseri. The present invention aims to provide the use of a composition comprising Lactobacillus gasseri for alleviating the decline in muscle mass and muscle function.

[0014] Another object of the present invention is to provide a composition for improving muscle strength and muscle endurance, the composition comprising Lactobacillus gasseri. The present invention aims to provide a method for improving muscle strength and muscle endurance, the method comprising administering Lactobacillus gasseri. The present invention aims to provide the use of a composition comprising Lactobacillus gasseri for improving muscle strength and muscle endurance.

[0015] Still another object of the present invention is to provide an anti-cancer adjuvant comprising Lactobacillus gasseri.

[0016] In order to achieve the above-mentioned object, the present invention provides a pharmaceutical composition for preventing or treating sarcopenia, the pharmaceutical composition comprising Lactobacillus gasseri BNR17 or its culture with the accession number KCTC 10902BP. The present invention also provides a method for preventing or treating sarcopenia, the method comprising administering Lactobacillus gasseri BNR17 or its culture with the accession number KCTC 10902BP. In addition, the present invention provides the use of Lactobacillus gasseri BNR17 or its culture with the accession number KCTC 10902BP for preparing a pharmaceutical composition for preventing or treating sarcopenia.

[0017] The present invention provides a food composition for alleviating the decline of muscle mass and muscle function, the food composition comprising Lactobacillus gasseri BNR17 or its culture with the accession number KCTC 10902BP. The present invention also provides a method for alleviating the decline of muscle mass and muscle function, the method comprising administering a food composition comprising Lactobacillus gasseri BNR17 or its culture with the accession number KCTC 10902BP. In addition, the present invention provides a use of Lactobacillus gasseri BNR17 or its culture with the accession number KCTC 10902BP in preparing a food composition for alleviating the decline of muscle mass and muscle function.

[0018] The present invention provides a composition for improving muscle strength and muscle endurance, the composition comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof. The present invention also provides a method for improving muscle strength and muscle endurance, the method comprising administering a composition comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof. In addition, the present invention provides a use of Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof in preparing a composition for improving muscle strength and muscle endurance.

[0019] The present invention provides an anticancer adjuvant, which comprises Lactobacillus gasseri BNR17 with the accession number of KCTC 10902BP or a culture thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figures 1 to 4 The results of comparison of the inhibitory effects of various Lactobacillus species microorganisms on sarcopenia caused by glucocorticoids as stress hormones are shown;

[0021] Figures 5 to 10The results of comparison of the inhibitory effects of various Lactobacillus gasseri strains on sarcopenia caused by the stress hormone glucocorticoid are shown;

[0022] Figures 11 to 22 The effect and mechanism of Lactobacillus gasseri BNR17 on sarcopenia caused by the stress hormone glucocorticoid are shown;

[0023] Figures 23 to 31 The effect of Lactobacillus gasseri BNR17 on sarcopenia caused by cisplatin, a drug used in anticancer chemotherapy, is shown;

[0024] Figures 32 to 39 The effect of Lactobacillus gasseri BNR17 on sarcopenia caused by tumors is shown;

[0025] Figures 40 to 43 shows the effect of Lactobacillus gasseri BNR17 on sarcopenia caused by obesity; and

[0026] Figures 44 to 46 The effect of Lactobacillus gasseri BNR17 on sarcopenia caused by aging is shown. DETAILED DESCRIPTION

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Generally speaking, the terms used herein and the experimental procedures described below are well known and typical in the art.

[0028] In a specific embodiment of the present invention, it has been confirmed that Lactobacillus gasseri BNR17 or its culture with accession number KCTC 10902BP can prevent or treat sarcopenia, alleviate the decline of muscle mass and muscle function, and improve muscle strength and muscle endurance, and can be used as an anti-cancer adjuvant.

[0029] Aspects of the present invention relate to a composition for preventing or treating sarcopenia, comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

[0030] Another aspect of the present invention relates to a food composition for alleviating the decline of muscle mass and muscle function, the composition comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

[0031] Still another aspect of the present invention relates to a composition for improving muscle strength and muscle endurance, the composition comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

[0032] Another aspect of the present invention relates to an anti-cancer adjuvant, comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

[0033] The strain according to the present invention has been deposited at the Korea Institute of Bioscience and Biotechnology on January 23, 2006 as KCTC 10902BP.

[0034] Lactobacillus gasseri BNR17 or a culture thereof with accession number KCTC 10902BP may exhibit:

[0035] Inhibits the reduction of MyoD (myoblast-determining protein-1);

[0036] Inhibits the reduction of MyHC (myosin heavy chain);

[0037] Inhibits the increase of MuRF1 (muscle RING-finger protein-1);

[0038] Inhibits the increase of MAFbx (muscle atrophy F-box, also known as atrogin-1);

[0039] Inhibit the increase of FOXO3 (forkhead box O3); and

[0040] Inhibits the increase of GDF-15 (growth differentiation factor 15).

[0041] In the case of a culture of a strain, "culture" may mean the result of culturing in a medium or liquid medium containing the strain. The culture may or may not contain the strain. The culture may be provided in a liquid or solid form, but the present invention is not limited thereto.

[0042] Various forms of the culture may be included, such as a concentrate, a dried product, or an extract of the culture.

[0043] The extract can be obtained by extracting using water, an organic solvent or the like, for example, water, a lower alcohol having 1 to 4 carbon atoms, hexane, chloroform, ethyl acetate or a mixed solvent thereof.

[0044] "Prevention" means any action that inhibits or delays the onset of a disease by administering a composition according to the present invention. "Treatment or alleviation" means any action that improves or beneficially alters the symptoms of a disease.

[0045] The decrease in muscle strength and muscle endurance may be caused by at least one factor selected from the group consisting of sarcopenia, muscle loss, muscle weakness, atonia, muscle atrophy and myasthenia gravis.

[0046] More specifically, decreased muscle strength and muscle endurance may be caused by at least one factor selected from the group consisting of sarcopenia, muscle loss, muscle weakness, atonia, muscle atrophy, myasthenia gravis, spastic spine syndrome, amyotrophic lateral sclerosis, cachexia, Charcot-Marie-Tooth disease, muscle degeneration, muscle degeneration and muscular dystrophy.

[0047] In the present invention, sarcopenia refers to a decrease in muscle mass in the body, and is a disease characterized by a decrease in muscle tissue due to a disease of the muscle itself, or a decrease in muscle tissue due to damage to the nerves that control the muscle.

[0048] Sarcopenia may be caused by a tumor or drug treatment, and in particular, the drug may be an anticancer drug. Tumor or drug treatment may cause a decrease in muscle mass and function, such as muscle loss, muscle loss, decreased muscle strength, decreased muscle endurance, etc., and the present invention has the use of preventing, alleviating or treating sarcopenia or decreased muscle mass and muscle function, because the prevention, alleviation and treatment effects on such decreased muscle function are confirmed in the embodiments.

[0049] The composition may further alleviate any symptom selected from the group consisting of increased fatigue, weight loss and decreased appetite.

[0050] The composition for preventing or treating sarcopenia according to the present invention can be used alone or in combination with other pharmaceutically active compounds, and can be used together with them in the form of appropriate preparations.

[0051] The composition of the present invention may further include a pharmaceutically acceptable carrier.

[0052] The composition of the present invention can be prepared into a pharmaceutical preparation using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. When preparing the preparation, the active ingredient is preferably mixed or diluted with a carrier, or encapsulated in a carrier in the form of a container.

[0053] Therefore, the composition of the present invention can be prepared and used in the form of oral preparations (such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc.), external preparations, suppositories and sterile injection solutions according to typical methods, and may further include appropriate carriers, excipients and diluents commonly used in preparing the composition.

[0054] Examples of carriers that can be included in the compositions of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. The preparation is prepared using a commonly used diluent or excipient, such as a filler, supplement, binder, wetting agent, disintegrant, surfactant, etc.

[0055] Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations are obtained by mixing the compound with at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

[0056] Liquid preparations for oral administration include suspensions, oral solutions, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavors, preservatives, etc. may also be included.

[0057] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous carriers, suspensions, emulsions, lyophilized preparations and suppositories. Non-aqueous carriers and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. As the basis of suppositories, Witepsol, Macrogol, Tween 61, cocoa butter, laurel oil, glycerin gelatin, etc. can be used.

[0058] The concentration of the active ingredient included in the composition can be determined in consideration of the therapeutic purpose, the patient's condition, the required time, etc., and is not limited to a specific range. The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical treatment, and the effective amount can be determined based on factors including: the type and severity of the patient's disease, drug activity, drug sensitivity, administration time, administration route and excretion rate, duration of treatment and concurrently used drugs, and other factors well known in the medical field.

[0059] The pharmaceutical composition of the present invention can be administered as a single therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. In addition, the composition can be administered once or multiple times. Taking all of the above factors into account, it is important that the amount of administration can achieve the maximum effect with the minimum amount without causing side effects, which can be easily determined by those skilled in the art.

[0060] As used herein, the term "administering" means introducing the pharmaceutical composition of the present invention into a patient's body by any appropriate method, and the composition of the present invention can be administered by various routes, such as oral or parenteral routes, as long as it can reach the target tissue.

[0061] The administration mode of the pharmaceutical composition of the present invention is not particularly limited, and can follow the methods commonly used in the art. As a non-limiting example of the administration mode, the composition can be administered orally or parenterally. Depending on the desired administration mode, the pharmaceutical composition according to the present invention can be prepared into various dosage forms.

[0062] Although there is no particular limitation on the frequency of administration of the composition of the present invention, the composition may be administered once a day or several times a day in divided doses.

[0063] A typical daily dose of the composition according to the invention may be 2.5 x 10 4 Up to 2.5x10 12 cfu / day, especially 2.5x10 6 Up to 2.5x10 10 cfu / day, which can be administered once or several times.

[0064] As used herein, the term "subject" may refer to any animal, including humans, that has or may develop a disease. The animal may be a mammal that needs to be treated for similar symptoms, such as not only humans, but also cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc., but not limited thereto.

[0065] The preventive or therapeutic methods of the present invention may specifically include administering a pharmaceutically effective amount of the composition to a subject who has developed or is at risk of developing a disease.

[0066] The food composition can be used to improve athletic performance.

[0067] The food composition of the present invention can be consumed daily and is therefore very useful because it can be expected to have a preventive or alleviating effect on a target disease.

[0068] As used herein, the term "alleviation" refers to any effect of improving or beneficially altering a disease by administering the composition of the present invention.

[0069] The food composition of the present invention is provided in the form of pills, powders, granules, precipitates, tablets, capsules or liquids, etc. Examples of foods to which the composition of the present invention can be added include various foods, such as beverages, chewing gum, tea, vitamin complexes, health products, etc.

[0070] There is no particular limitation on other ingredients except for the composition containing the activity of preventing and treating the target disease, which includes the active substance or its active ingredient or its physiologically acceptable salt as an essential ingredient that can be included in the food composition of the present invention. Like typical foods, various herbal extracts, food supplements or natural carbohydrates can be included as additional ingredients.

[0071] The food may be a functional health food. Here, "functional health food" refers to a food with high medical effects, which, after processing, can effectively exhibit biological regulation functions in addition to providing nutrition. Functional health foods can be manufactured in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. to obtain useful effects in preventing or alleviating diseases.

[0072] Functional health food compositions can be made into food, particularly functional food. Functional food of the present invention can include ingredients often added during food production, and examples thereof can include protein, carbohydrate, fat, nutrients and seasoning. For example, when manufactured as a beverage, in addition to active ingredients, natural carbohydrates or seasonings as additional ingredients can also be included. Natural carbohydrates preferably include monosaccharides (such as glucose, fructose, etc.), disaccharides (such as maltose, sucrose, etc.), oligosaccharides, polysaccharides (such as dextrin, cyclodextrin, etc.) or sugar alcohols (such as xylitol, sorbitol, erythritol, etc.). Seasonings can be natural seasonings (such as, thaumatin, stevia extract, etc.) or synthetic seasonings (such as saccharin, aspartame, etc.).

[0073] There is no particular limitation on the types of functional health foods. Examples of functional health foods may include dairy products, beverages, tea drinks, alcoholic beverages, and vitamin complexes, and may include all health foods in a typical sense.

[0074] In addition, it may also include various nutrients, vitamins, electrolytes, flavors, colorants, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc.

[0075] The present invention relates to an anticancer adjuvant, which comprises Lactobacillus gasseri BNR17 with a registration number of KCTC 10902BP or a culture thereof. Since Lactobacillus gasseri BNR17 has been confirmed to be effective in preventing or treating sarcopenia caused by tumors or drug treatment using anticancer drugs, the anticancer drug and the anticancer adjuvant can be administered simultaneously or sequentially.

[0076] The anticancer drug may be at least one selected from the group consisting of cisplatin, doxorubicin, irinotecan, paclitaxel, daunorubicin, docetaxel, 5-fluorouracil and the like.

[0077] As used herein, the term "anticancer adjuvant" refers to an adjuvant that has the effect of reducing the side effects of anticancer drugs during anticancer treatment. The side effects of anticancer drugs may include sarcopenia, decreased muscle mass and muscle function, decreased muscle strength and muscle endurance, fatigue, weight loss, decreased appetite, etc.

[0078] In addition to including Lactobacillus gasseri BNR17 as an active ingredient, the anticancer adjuvant may further include at least one active ingredient that exhibits the same or similar function. During clinical administration, the anticancer adjuvant may be administered orally or parenterally, and when parenterally, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine dura mater injection, lateral cerebroventricular injection or intrathoracic injection may be performed. The anticancer adjuvant may be used in the form of a general pharmaceutical preparation.

[0079] Anticancer adjuvants can be used alone or in combination with surgery, radiotherapy, hormone therapy, chemotherapy, and the use of biological products.

[0080] The daily dose of anticancer adjuvant can be 2.5x10 4 Up to 2.5x10 12 cfu / day, especially 2.5x10 6 Up to 2.5x10 10 cfu / day, it is preferably administered once or several times a day, but its scope varies with the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate and disease severity. The anticancer adjuvant of the present invention can be administered with various parenteral preparations during actual clinical administration. During preparation, commonly used diluents or excipients are used, such as fillers, supplements, adhesives, wetting agents, disintegrants, surfactants, etc. The preparations for parenteral administration can include sterile aqueous solutions, non-aqueous carriers, suspensions, emulsions, lyophilized preparations and suppositories. Non-aqueous carriers and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. As the basis of suppositories, Witepsol, Macrogol, Tween 61, cocoa butter, laurel oil, glycerin gelatin, etc. can be used.

[0081] Yet another aspect of the present invention relates to a method for inhibiting the decline in muscle mass and muscle function associated with sarcopenia using Lactobacillus gasseri BNR17: a method for inhibiting the decline in muscle strength and muscle endurance; a method for inhibiting the reduction of myosin and myoblast determining protein 1 (MyoD) and a method for inhibiting the increase of growth differentiation factor-15 (GDF-15).

[0082] Myosin controls muscle contraction through interaction with actin, and myoblast-determining protein 1 (MyoD) is a transcription factor that plays a key role in increasing muscle mass, and its expression is activated by exercise (Rudnicki et al., Cell 75(7):1351-1359, 1993). The reduction of proteins that control muscle function and muscle mass is triggered by stress, obesity, aging, drugs, tumorigenesis, etc., and is the most direct factor leading to sarcopenia.

[0083] Muscle RING-finger 1 (MuRF1) and muscle atrophy F-box (MAFbx) are muscle-specific ubiquitin E3 ligases that play a key role in the ubiquitin-dependent proteolysis of actin-myosin and MyoD (Polge et al., FASEBJ 25: 3790-3802, 2011; Lokireddy et al., Am J Physiol Cell Physiol 303: C512-C529, 2012). Moreover, the expression of MuRF1 and MAFbx in muscle is achieved by the forkhead box O3 (FOXO3) transcription factor. (Bodine et al., Am J Physiol Endocrinol Metab 307: E469-E484, 2014).

[0084] Growth differentiation factor-15 (GDF-15) is known to be an indicator of tissue damage that increases when various tissues including the lungs, kidneys, and liver are damaged, and damage to various tissues in the human body causes decreased muscle function (Zimmers et al., Shock 23: 543-548, 2005). In particular, since GDF-15 is associated with sarcopenia caused by tumors, it is reported that when GDF-15 is inhibited using methods such as monoclonal antibodies, sarcopenia caused by tumors can be treated (Wu et al., Annals of Oncology 31: S245-S259, 2020).

[0085] A better understanding of the present invention can be obtained through the following examples. These examples are only used to illustrate the present invention and should not be interpreted as limiting the scope of the present invention, which is obvious to those of ordinary skill in the art.

[0086] Example 1: Comparative experiment on the inhibitory effects of various lactobacilli on sarcopenia caused by stress hormones

[0087] Lactobacillus species such as Lactobacillus casei (LC: Accession No. KCTC3109 T), Lactobacillus paragasseri (LP: Accession No. KCTC 3510 T ), Lactobacillus ruteri (LR: Accession No. KCTC 3594 T ) and Lactobacillus gasseri (LG: Accession No. KCTC 10902BP) were isolated from fermented foods, human feces, human milk, etc., and cultured in MRS medium for 16 hours.

[0088] The experimental animals were 4-week-old female Balb / c mice (18 to 20 g) provided by Central Lab.Animal Inc. and acclimated for one week in the laboratory animal facility and then used for the experiment. During the experimental period, solid feed and water were freely available, and the temperature (22 ± 2°C), relative humidity (60 ± 5%) and 12-hour light / dark cycle of the breeding room were maintained.

[0089] The mice were divided into a control group and a glucocorticoid (stress hormone) treated group, and the glucocorticoid treated group was further divided into a carrier administration group and a lactobacillus administration group. The control group was intraperitoneally injected with 200 μl of normal saline, and the glucocorticoid treated group was intraperitoneally injected with 30 mg / kg of glucocorticoid, once a day.

[0090] Meanwhile, in the glucocorticoid-treated group, distilled water was administered to the vehicle-administered group, and various lactobacilli such as LC, LP, LR, LG, and LRG (a 1:1 mixture of LR and LG) were orally administered to the lactobacilli-administered group at a dose of 10 8 cfu / mouse (converted to human dose is 2.5x10 10 cfu / person for 3 weeks (2.5x10 10 cfu / person=10 8 cfu / 20g x 60,000g / 12, standard weight of mice: 20g, standard weight of humans: 60kg, human / mouse dose equivalence factor: 12).

[0091] After administration, the muscular endurance of mice was measured using a treadmill (Columbus Instrument, USA). Muscular endurance was measured by the maximum exercise time and maximum exercise distance until the mice were exhausted and could no longer run. The lean body mass of each mouse was measured by dual-energy X-ray absorptiometry using InAlyzer (Medikors, South Korea). After the experiment was terminated, the mice were killed and the weight of the gastrocnemius and quadriceps femoris was measured.

[0092] Example 2: Comparison of the inhibitory effects of various lactobacilli on sarcopenia caused by stress hormones

[0093] Based on the results of measuring the muscle endurance of mice using a treadmill, the treadmill running time and distance of the glucocorticoid group were both very low compared with the control group. Among the groups administered with various lactobacilli, the muscle endurance of the group administered with Lactobacillus gasseri (LG) was significantly restored ( Figure 1 and Figure 2 ). In addition, in the Lactobacillus gasseri-administered group, the weight of the gastrocnemius muscle increased significantly ( Figure 3 Compared with the control group, the lean body mass measured by dual-energy X-ray absorptiometry was significantly reduced in the glucocorticoid group, but significantly increased in the Lactobacillus gasseri group ( Figure 4 ).

[0094] Among various Lactobacillus species, Lactobacillus gasseri exhibited a significant sarcopenia-suppressing effect, so Lactobacillus gasseri was used for subsequent experiments.

[0095] Example 3: Comparative experiment on the inhibitory effects of various Lactobacillus gasseri strains on sarcopenia caused by stress hormones

[0096] Various Lactobacillus gasseri strains, namely H65 (Lactobacillus gasseri H65: Accession No. KCCM 80404), H30 (Lactobacillus gasseri H30: Accession No. KCCM 80403), RM2 (Lactobacillus gasseri RM2, Accession No. KCCM 80405), FF557 (Lactobacillus gasseri FF557, Accession No. KCCM 80406) and BNR17 were cultured in MRS medium for 16 hours.

[0097] The experimental animals were 4-week-old female Balb / c mice (18 to 20 g) provided by Central Laboratory Animal Co., Ltd. and acclimated for one week in the laboratory animal facility and then used for the experiment. During the experimental period, solid feed and water were freely available, and the temperature (22 ± 2°C), relative humidity (60 ± 5%) and 12-hour light / dark cycle of the breeding room were maintained.

[0098] The mice were divided into a control group and a glucocorticoid (stress hormone) treated group, and the glucocorticoid treated group was further divided into a carrier administration group and a lactobacillus administration group. The control group was intraperitoneally injected with 200 μl of normal saline, and the glucocorticoid treated group was intraperitoneally injected with 30 mg / kg of glucocorticoid, once a day.

[0099] Meanwhile, in the glucocorticoid-treated group, distilled water was administered to the vehicle-administered group, and various Lactobacillus gasseri strains, such as H65, H30, RM2, FF557, and BNR17, were orally administered to the Lactobacillus-administered group at a dose of 108 cfu / mouse (converted to human dose is 2.5x10 10 cfu / person) for 16 days (2.5x10 10 cfu / person=10 8 cfu / 20g x 60,000g / 12, standard weight of mice: 20g, standard weight of humans: 60kg, human / mouse dose equivalence factor: 12).

[0100] The weight change and final body weight during the administration period are measured. The muscle endurance of mice is measured using a treadmill (Columbus, USA). Muscle endurance is quantified by the maximum exercise time and maximum exercise distance until the mice are exhausted and can no longer run. The forelimb muscle strength of mice is measured using a handgrip dynamometer (Bioseb, France). After the experiment is terminated, mice are killed and the weight of the gastrocnemius and quadriceps femoris is measured.

[0101] Example 4: Comparison of the inhibitory effects of various Lactobacillus gasseri strains on sarcopenia caused by stress hormones

[0102] By administering glucocorticoids, mice lose weight. Among the glucocorticoid-treated groups, only the group administered with BNR17 showed less weight loss among various Lactobacillus gasseri strains, and other strains showed similar or more severe weight loss ( Figure 5 The final body weight of the glucocorticoid-treated group was significantly decreased compared with the control group, and glucocorticoid-induced weight loss was significantly suppressed only in the BNR17-administered group ( Figure 6 ). Compared with the control group, the quadriceps weight of the glucocorticoid-treated group was significantly decreased, and the glucocorticoid-induced quadriceps weight loss was significantly inhibited only in the BNR17-administered group ( Figure 7 Based on the results of measuring mouse muscle strength (grip strength) using a handgrip dynamometer, the grip strength of the glucocorticoid-treated group was significantly decreased compared with the control group, and the decrease in grip strength caused by glucocorticoid was significantly suppressed only in the BNR17-administered group ( Figure 8 ).

[0103] Based on the results of measuring the muscle endurance of mice using a treadmill, the treadmill running time and distance of the glucocorticoid group were both very low compared to the control group. Among the various Lactobacillus gasseri strains, muscle endurance was significantly restored in the group administered with BNR17 ( Fig. 9 and 10 ).

[0104] Among various Lactobacillus gasseri strains, Lactobacillus gasseri BNR17 exhibited a significant sarcopenia inhibitory effect, so Lactobacillus gasseri BNR17 was used for subsequent experiments.

[0105] Example 5: Experiment on the inhibitory effect and mechanism of sarcopenia caused by stress hormones

[0106] The Lactobacillus gasseri BNR17 strain was cultured in MRS medium for 16 hours.

[0107] The experimental animals were 4-week-old female Balb / c mice (18 to 20 g) provided by Central Laboratory Animal Co., Ltd. and acclimated for one week in the laboratory animal facility and then used for the experiment. During the experimental period, solid feed and water were freely available, and the temperature (22 ± 2°C), relative humidity (60 ± 5%) and 12-hour light / dark cycle of the breeding room were maintained.

[0108] The mice were divided into a control group and a glucocorticoid (stress hormone) group, and the glucocorticoid group was further divided into a vehicle administration group and a Lactobacillus gasseri administration group. The control group was intraperitoneally injected with 200 μl of normal saline, and the glucocorticoid group was intraperitoneally injected with 30 mg / kg of glucocorticoid once a day.

[0109] Meanwhile, in the glucocorticoid group, the vehicle-administered group was given distilled water, and the Lactobacillus gasseri-administered group was given 10 7 Up to 10 8 cfu / mouse dose (converted to human dose is 2.5x10 9 Up to 2.5x10 10 cfu / person) was orally administered with Lactobacillus gasseri for 14 days.

[0110] After administration, the muscle endurance of mice was measured using a treadmill (Columbus, USA). Muscle endurance was quantified by the maximum exercise time and maximum exercise distance until the mice were exhausted and could no longer run. In addition, a handgrip dynamometer (Bioseb, France) was used to measure the forelimb muscle strength of mice. InAlyzer (Medikors, Korea) was used to measure the lean body mass of the whole body and hind legs of each mouse by dual-energy X-ray absorptiometry.

[0111] After the experiment was terminated, mice were killed and the weights of quadriceps and gastrocnemius were measured. Protein was extracted from the quadriceps of each mouse and the levels of myosin heavy chain (MyHC), myoblast-determining protein 1 (MyoD), MuRF1, MAFbx, FOXO3 and β-actin (control protein) were measured by Western blotting and quantitatively analyzed compared to β-actin using ImageJ software (NIH, Bethesda, Maryland (MD), USA).

[0112] Example 6: Confirmation of the inhibitory effect and mechanism of Lactobacillus gasseri BNR17 on sarcopenia caused by stress hormones

[0113] Based on the results of measuring the muscle endurance of mice using a treadmill, the treadmill running time and distance of the load body-administered group in the glucocorticoid (stress hormone) group were both very low compared to the control group. However, in the group administered with Lactobacillus gasseri BNR17, muscle endurance was significantly restored ( Fig.11 and 12 ). Compared with the control group, the muscle strength (grip strength) of mice in the glucocorticoid group was significantly decreased in the carrier group, but the grip strength was significantly restored in the Lactobacillus gasseri BNR17 group ( Fig.13 In the Lactobacillus gasseri BNR17-administered group, the weights of the gastrocnemius and quadriceps muscles increased significantly ( Fig.14 and 15 ). Compared with the control group, the whole body lean body mass and hind limb lean body mass measured by dual-energy X-ray absorptiometry were significantly reduced in the glucocorticoid-treated group, but significantly increased in the Lactobacillus gasseri BNR17-treated group ( Fig.16 and 17 ).

[0114] Muscle contraction occurs through the interaction of myosin and actin. Based on the results of the measurement of myosin heavy chain (MyHC) levels (which plays a key role in muscle contraction) by extracting proteins from quadriceps femoris, the MyHC levels were decreased in the load-administered group of the glucocorticoid group compared with the control group, but the MyHC levels were significantly increased in the Lactobacillus gasseri BNR17-administered group compared with the load-administered group of the glucocorticoid group ( Fig.18 ).

[0115] Myoblast-determining protein 1 (MyoD) is a transcription factor that plays a key role in increasing muscle mass, and its expression is activated by exercise (Rudnicki et al., Cell 75(7):1351-1359, 1993). Based on the results of MyoD level measurement by extracting protein from quadriceps femoris, MyoD level was decreased in the load-administered group of the glucocorticoid group compared with the control group, but MyoD level was significantly increased in the Lactobacillus gasseri BNR17-administered group compared with the load-administered group of the glucocorticoid group ( Fig.19 ).

[0116] Increased levels of MyHC (which plays a key role in muscle contraction) and MyoD (which plays a key role in increasing muscle mass) suggest that Lactobacillus gasseri BNR17 has a direct mechanism of action on increases in muscle endurance, muscle strength, and muscle mass.

[0117] The levels of MuRF1 and MAFbx, which cause ubiquitin-dependent proteolysis of MyHC and MyoD, were increased in the glucocorticoid-treated group compared with the control group, but these levels were significantly decreased in the Lactobacillus gasseri BNR17-treated group compared with the glucocorticoid-treated group ( Fig. 20 and 21 ).

[0118] The level of FOXO3, a transcription factor that causes the transcription of MuRF1 and MAFbx, was also increased in the glucocorticoid-treated group compared with the control group, but the level of FOXO3 in the Lactobacillus gasseri BNR17-treated group was significantly decreased compared with the glucocorticoid-treated group ( Fig. 22 ).

[0119] Example 7: Experiment on the inhibitory effect on sarcopenia caused by drugs

[0120] The experimental animals were 4-week-old female Balb / c mice (18 to 20 g) provided by Central Laboratory Animal Co., Ltd. and acclimated for one week in the laboratory animal facility and then used for the experiment. During the experimental period, solid feed and water were freely available, and the temperature (22 ± 2°C), relative humidity (60 ± 5%) and 12-hour light / dark cycle of the breeding room were maintained.

[0121] Cisplatin is used to prepare a drug-induced sarcopenia model mouse. Drugs used in anticancer chemotherapy, including cisplatin, cause sarcopenia as a major side effect, which reduces cure rates and quality of life (Davis MP et al., Annals of Palliative Medicine, 8(1):86-101, 2019).

[0122] The mice were divided into a control group and a cisplatin group, and the cisplatin group was further divided into a vehicle administration group and a Lactobacillus gasseri administration group. The control group was intraperitoneally injected with 200 μl of saline, and the cisplatin group was intraperitoneally injected with 3 mg / kg cisplatin four times at intervals of two days.

[0123] Meanwhile, in the cisplatin group, the vehicle-administered group was administered with distilled water, and the Lactobacillus gasseri-administered group was administered with 10 4 Up to 10 7 cfu / mouse dose (converted to human dose is 2.5x10 6 Up to 2.5x10 9 cfu / person) was orally administered with Lactobacillus gasseri for 9 days.

[0124] After administration, the muscular endurance of mice was measured using a treadmill (Columbus, USA). Muscular endurance was quantified by the maximum exercise time and maximum exercise distance until the mice were exhausted and could no longer run. In addition, a handgrip dynamometer (Bioseb, France) was used to measure the forelimb muscle strength of mice.

[0125] After the experiment was terminated, mice were killed, blood was collected from the heart, and serum was separated by centrifugation. Protein was extracted from the quadriceps of each mouse and the levels of myosin heavy chain (MyHC), myoblast-determining protein 1 (MyoD) and β-actin (control protein) were measured by Western blotting, and quantitative analysis was performed compared to β-actin using ImageJ software (NIH, Bethesda, Maryland (MD), the United States). GDF-15 in muscle and serum was quantified by ELISA.

[0126] Example 8: Confirmation of the effect of Lactobacillus gasseri BNR17 on drug-induced sarcopenia

[0127] Based on the results of measuring the muscle endurance of mice using a treadmill, the treadmill running time and distance of the cisplatin-treated group were significantly reduced compared with the control group. However, an excellent muscle endurance recovery effect was confirmed in the Lactobacillus gasseri BNR17-treated group ( Fig.23 and 24 ). Compared with the control group, the muscle strength (grip strength) of mice in the cisplatin-treated group was significantly decreased, but the grip strength was significantly restored in the Lactobacillus gasseri BNR17-treated group ( Fig.25 In the Lactobacillus gasseri BNR17-administered group, the weights of the gastrocnemius and quadriceps muscles increased significantly ( Fig.26 and 27 ).

[0128] Muscle contraction occurs through the interaction of myosin and actin. Based on the results of MyHC (myosin heavy chain) level measurement (which plays a key role in muscle contraction) by extracting proteins from quadriceps femoris, the MyHC level was decreased in the cisplatin-treated group compared with the control group, but the MyHC level was significantly increased in the Lactobacillus gasseri BNR17-treated group compared with the cisplatin-treated group ( Fig.28 ).

[0129] Myoblast-determining protein 1 (MyoD) is a transcription factor that plays a key role in increasing muscle mass, and its expression is activated by exercise (Rudnicki et al., Cell 75(7):1351-1359, 1993). Based on the results of MyoD level measurement by extracting protein from quadriceps femoris, the MyoD level in the cisplatin-treated group decreased compared with the control group, but the MyoD level in the Lactobacillus gasseri BNR17-treated group increased significantly compared with the cisplatin-treated group ( Fig.29 ).

[0130] Increased levels of MyHC (which plays a key role in muscle contraction) and MyoD (which plays a key role in increasing muscle mass) suggest that Lactobacillus gasseri has a direct mechanism of action on increases in muscle endurance, muscle strength, and muscle weight.

[0131] Based on the quantitative results of GDF-15 in muscle, compared with the control group, the level of GDF-15 in muscle of the cisplatin-treated group was greatly increased, but the level of GDF-15 in muscle of the Lactobacillus gasseri-treated group was significantly decreased ( Fig.30 ). The quantitative results of GDF-15 in serum showed the same pattern as the GDF-15 levels in muscle ( Fig.31 ).

[0132] Example 9: Experiment on the inhibitory effect on tumor-induced sarcopenia

[0133] The experimental animals were 4-week-old female Balb / c mice (18 to 20 g) provided by Central Laboratory Animal Co., Ltd. and acclimated for one week in the laboratory animal facility and then used for the experiment. During the experimental period, solid feed and water were freely available, and the temperature (22 ± 2°C), relative humidity (60 ± 5%) and 12-hour light / dark cycle of the breeding room were maintained.

[0134] The mice were divided into a control group and a tumor group, and the tumor group was further divided into a vehicle administration group and a Lactobacillus gasseri administration group. The control group was subcutaneously injected with 200 μl of saline, and the tumor group was subcutaneously injected with 10 C26 colon cancer cells. 6 cells / mouse.

[0135] After 14 days, when tumors were obviously formed, the vehicle-administered group was administered with distilled water, and the comparative drug group was orally administered with 160 mg / kg of megestrol acetate (MA), which is the most commonly used drug for treating weight loss in cancer patients, once a day for 7 days (mouse dose calculation: 160 mg / kg = 800 mg / 60 kg x 12, daily human dose: 800 mg, human standard body weight: 60 kg, human / mouse dose equivalent factor: 12).

[0136] The Lactobacillus gasseri group was given 10 5 Up to 10 7 Lactobacillus gasseri BNR17 was orally administered at a dose of 100 mg / mice for 7 days.

[0137] After drug administration, the muscle endurance of mice was measured using a treadmill (Columbus, USA), and the muscle strength of mice was measured using a handgrip dynamometer (Bioseb, France).

[0138] After the experiment was terminated, mice were killed, blood was collected from the heart, and serum was separated by centrifugation. Protein was extracted from the quadriceps of each mouse and the levels of myosin heavy chain (MyHC), myoblast-determining protein 1 (MyoD) and β-actin (control protein) were measured by Western blotting, and quantitative analysis was performed compared to β-actin using ImageJ software (NIH, Bethesda, Maryland (MD), the United States). GDF-15 in muscle and serum was quantified by ELISA.

[0139] Example 10: Confirmation of the effect of Lactobacillus gasseri BNR17 on sarcopenia caused by tumors

[0140] Based on the results of measuring the muscle endurance of mice using a treadmill, the treadmill running time and distance of the tumor group administered with the carrier were both very low compared with the control group. However, in the group administered with Lactobacillus gasseri BNR17, muscle endurance was significantly improved ( Fig.32 and 33 ). Compared with the control group, the muscle strength (grip strength) of mice in the tumor group administered with the carrier was significantly decreased, but the grip strength was significantly restored in the group administered with Lactobacillus gasseri BNR17 ( Fig.34 ).

[0141] In addition, based on the results of the measurement and comparison of the quadriceps weight, the quadriceps weight of the tumor group was significantly reduced in the carrier-administered group compared with the control group, but the muscle weight in the Lactobacillus gasseri BNR17-administered group was significantly increased ( Fig.35 ).

[0142] Based on the results of MyHC (myosin heavy chain) level measurement (which plays a key role in muscle contraction) by extracting proteins from quadriceps femoris, MyHC level was decreased in the vehicle-administered group of the tumor group compared with the control group, but MyHC level was significantly increased in the Lactobacillus gasseri BNR17-administered group compared with the vehicle-administered group of the tumor group ( Fig.36 ).

[0143] Based on the results of MyoD (which plays a key role in increasing muscle mass) level measurement by extracting protein from quadriceps femoris, MyoD level was decreased in the vehicle-administered group of the tumor group compared with the control group, but MyoD level was significantly increased in the Lactobacillus gasseri BNR17-administered group compared with the vehicle-administered group of the tumor group ( Fig.37 ).

[0144] Increased levels of MyHC (which plays a key role in muscle contraction) and MyoD (which plays a key role in increasing muscle mass) suggest that Lactobacillus gasseri has a direct mechanism of action on increases in muscle endurance, muscle strength, and muscle weight.

[0145] Based on the quantitative results of GDF-15 in muscle, compared with the control group, the level of GDF15 in muscle of the tumor group in the carrier administration group was greatly increased, but the level of GDF-15 in muscle of the Lactobacillus gasseri BNR17 administration group was significantly decreased ( Fig.38 ). The quantitative results of GDF-15 in serum showed the same pattern as the GDF-15 levels in muscle ( Fig.39 ).

[0146] In terms of suppressing tumor-induced sarcopenia, the 10-fold increase in sarcopenia was compared with megestrol acetate (MA), the most commonly used drug for weight loss in cancer patients. 7 cfu / mouse (2.5x10 9 / person) showed the same or better therapeutic effect.

[0147] Example 11: Experiment on the inhibitory effect on sarcopenia caused by obesity

[0148] The experimental animals were 4-week-old female Balb / c mice (18 to 20 g) provided by Central Laboratory Animal Co., Ltd. and acclimated for one week in the laboratory animal facility and then used for the experiment. During the experimental period, solid feed and water were freely available, and the temperature (22 ± 2°C), relative humidity (60 ± 5%) and 12-hour light / dark cycle of the breeding room were maintained.

[0149] The mice were divided into a control group and an obese group, and the obese group was further divided into a carrier administration group and a Lactobacillus gasseri BNR17 administration group. The control group was fed with a regular feed, and the obese group was fed with a high-fat diet (70% fat) for 8 weeks to induce obesity.

[0150] Thereafter, in the obese group, distilled water was administered to the vehicle-administered group, and Lactobacillus gasseri BNR17 was orally administered to the Lactobacillus gasseri-administered group at a dose of 10 7 Up to 10 8 cfu / mouse (converted to human dose is 2.5x10 9Up to 2.5x10 10 cfu / person) for 8 weeks.

[0151] After administration, the muscular endurance of mice was measured using a treadmill (Columbus, USA). Muscular endurance was quantified by the maximum exercise time and maximum exercise distance until the mice were exhausted and could no longer run. In addition, a handgrip dynamometer (Bioseb, France) was used to measure the forelimb muscle strength of mice. The lean body mass of each mouse was measured by dual-energy X-ray absorptiometry using InAlyzer (Medikors, Korea).

[0152] Example 12: Confirmation of the inhibitory effect of Lactobacillus gasseri BNR17 on sarcopenia caused by obesity

[0153] Based on the results of measuring the muscle endurance of mice using a treadmill, the treadmill running time and distance of the load body-administered group in the obese group were both very low compared to the control group. However, in the Lactobacillus gasseri BNR17-administered group, muscle endurance was significantly restored ( Fig.40 and 41 ). Compared with the control group, the muscle strength (grip strength) of mice in the obese group administered with the carrier was significantly decreased, but the grip strength was significantly restored in the group administered with Lactobacillus gasseri BNR17 ( Fig.42 ). Compared with the control group, the lean body mass of the hind limbs of the obese group treated with the carrier was significantly reduced as measured by dual-energy X-ray absorptiometry, but the lean body mass of the hind limbs of the group treated with Lactobacillus gasseri BNR17 was significantly increased ( Fig.43 ).

[0154] Example 13: Experiment on the inhibitory effect on sarcopenia caused by aging

[0155] The experimental animals were 4-week-old female Balb / c mice (18 to 20 g) provided by Central Laboratory Animal Co., Ltd. and acclimated for one week in the laboratory animal facility and then used for the experiment. During the experimental period, solid feed and water were freely available, and the temperature (22 ± 2°C), relative humidity (60 ± 5%) and 12-hour light / dark cycle of the breeding room were maintained.

[0156] The mice were divided into a control group and an aging-induced group, and the aging-induced group was further divided into a carrier administration group and a Lactobacillus gasseri BNR17 administration group. The control group was intraperitoneally injected with 200 μl of normal saline, and the aging-induced group was intraperitoneally injected with 200 mg / kg of D-galactose for 6 weeks to induce aging (Chang L et al., Journal of Medicinal Food 17(3):357-364, 2014).

[0157] Meanwhile, in the senescence-induced group, distilled water was administered to the carrier-administered group, and Lactobacillus gasseri BNR17 was orally administered to the D-galactose-administered group at a dose of 10 6 Up to 10 8 cfu / mouse (converted to human dose is 2.5x10 8 Up to 2.5x10 10 cfu / person).

[0158] After administration, the muscular endurance of mice was measured using a treadmill (Columbus, USA). Muscular endurance was quantified by the maximum exercise time and maximum exercise distance until the mice were exhausted and could no longer run. In addition, a handgrip dynamometer (Bioseb, France) was used to measure the forelimb muscle strength of mice.

[0159] Example 14: Confirmation of the inhibitory effect of Lactobacillus gasseri BNR17 on sarcopenia caused by aging

[0160] Based on the results of measuring the muscle endurance of mice using a treadmill, both the treadmill running time and distance of the aging-induced group administered with the carrier were very low compared with the control group. However, in the group administered with Lactobacillus gasseri BNR17, muscle endurance was significantly restored ( Fig.44 and 45 ). Compared with the control group, the muscle strength (grip strength) of mice in the aging-induced group was significantly decreased in the carrier-administered group, but the grip strength was significantly restored in the Lactobacillus gasseri BNR17-administered group ( Fig.46 ).

[0161] In summary, a decrease in MyoD (myoblast determining protein-1) (which plays an important role in increasing muscle mass) and MyHC (myosin heavy chain) (which plays a major role in muscle contraction) are direct factors leading to sarcopenia, which is believed to be caused by an increase in MuRF1 (muscle RING-finger protein-1) and MAFbx (muscle atrophy F-box, also known as atroin-1) (which leads to ubiquitin-dependent proteolysis of MyoD and MyHC) as well as an increase in FOXO3 (forkhead box O3) (which acts as a transcription factor for MuRF1 and MAFbx).

[0162] Lactobacillus gasseri BNR17 can effectively inhibit the decline of muscle function and muscle quality by inhibiting the reduction of MyHC and MyoD and the increase of MuRF1, MAFbx and FOXO3 caused by various factors such as stress, drugs, tumors, obesity, aging, etc. Therefore, Lactobacillus gasseri BNR17 can be used as a pharmaceutical composition for preventing and treating sarcopenia caused by various factors including stress, drugs, tumors, obesity and aging, and as a food for improving muscle quality and muscle function or muscle strength and muscle endurance.

[0163] After describing the specific parts of the present invention in detail above, it will be clear to those skilled in the art that these specific descriptions are only preferred embodiments and the scope of the present invention is not limited thereto. Therefore, the essential scope of the present invention will be defined by the appended claims and their equivalents.

[0164] Industrial Applicability

[0165] According to an embodiment of the present invention, the pharmaceutical composition and the food composition can prevent or treat sarcopenia and improve muscle mass and muscle function or muscle strength and muscle endurance, thereby maintaining and improving health and quality of life under various conditions (such as stress, obesity, aging, drugs, tumor occurrence, etc.).

[0166] The effects of the present invention are not limited to the above contents, and those skilled in the art will clearly understand other effects not mentioned herein through this specification.

[0167]

Claims

1. A pharmaceutical composition for preventing or treating sarcopenia, comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

2. The pharmaceutical composition according to claim 1, wherein The sarcopenia is caused by stress, obesity, aging, drugs or tumors.

3. The pharmaceutical composition according to claim 1, wherein The Lactobacillus gasseri BNR17 or a culture thereof exhibits: Inhibits the reduction of MyoD (myoblast-determining protein-1); Inhibits the reduction of MyHC (myosin heavy chain); Inhibits the increase of MuRF1 (muscle RING-finger protein-1); Inhibits the increase of MAFbx (muscle atrophy F-box, atrogin-1); Inhibit the increase of FOXO3 (forkhead box O3); and Inhibits the increase of GDF-15 (growth differentiation factor 15).

4. A food composition for alleviating the decline of muscle mass and muscle function, comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

5. The food composition according to claim 4, wherein The decrease in muscle mass and muscle function is caused by stress, obesity, aging, drugs or tumors.

6. The food composition according to claim 4, wherein The Lactobacillus gasseri BNR17 or a culture thereof exhibits: Inhibits the reduction of MyoD (myoblast-determining protein-1); Inhibits the reduction of MyHC (myosin heavy chain); Inhibits the increase of MuRF1 (muscle RING-finger protein-1); Inhibits the increase of MAFbx (muscle atrophy F-box, atrogin-1); Inhibit the increase of FOXO3 (forkhead box O3); and Inhibits the increase of GDF-15 (growth differentiation factor 15).

7. A composition for improving muscle strength and muscle endurance, comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

8. The composition according to claim 7, wherein The Lactobacillus gasseri BNR17 or a culture thereof exhibits: Inhibits the reduction of MyoD (myoblast-determining protein-1); Inhibits the reduction of MyHC (myosin heavy chain); Inhibits the increase of MuRF1 (muscle RING-finger protein-1); Inhibits the increase of MAFbx (muscle atrophy F-box, atrogin-1); Inhibit the increase of FOXO3 (forkhead box O3); and Inhibits the increase of GDF-15 (growth differentiation factor 15).

9. An anticancer adjuvant comprising Lactobacillus gasseri BNR17 with accession number KCTC 10902BP or a culture thereof.

10. The anticancer adjuvant according to claim 9, which is used to alleviate sarcopenia, decreased muscle mass and muscle function, or decreased muscle strength and muscle endurance caused by anticancer drugs.

Images